Treatment of obesity: an update on anti‐obesity medications

The information presented in this article provides an overview of physiological agents, therapeutics in current use, and medications that have been extensively used in the past but are no longer available, or are not classically considered as anti‐obesity drugs. The authors present an extensive review on the criteria for anti‐obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral action energetic homeostasis (nutrients, monoamines and peptides), and on β‐phenethylamine pharmacological‐derivative agents (fenfluramine, dexfenfluramine, phentermine, diethylpropion, fenproporex and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrine, phenylpropanolamine), a phenylpropanolamine oxy‐tri‐fluor‐phenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials longer than 10 weeks in duration is also presented for medications used in the management of obesity.

[1]  A. Kornhaber.  Obesity-depression: clinical evaluation with a new anorexigenic agent. , 1973, Psychosomatics.

[2]  C. Lucas,et al.  Orlistat in the long-term treatment of obesity in primary care settings. , 2000, Archives of family medicine.

[3]  P. Turner,et al.  Direct measurement of the anorectic activity of diethylpropion (Tenuate Dospan). , 1968, The Journal of clinical pharmacology and the journal of new drugs.

[4]  A. J. Hadler.  Mazindol, a new non-amphetamine anorexigenic agent. , 1972, The Journal of clinical pharmacology and new drugs.

[5]  G. Bray.  Obesity: a time bomb to be defused , 1998, The Lancet.

[6]  O. Pedersen,et al.  Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients. , 1993, Acta endocrinologica.

[7]  A. Rissanen,et al.  Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. , 2000, Archives of internal medicine.

[8]  Alessandra Rascovski,et al.  Eficácia e tolerabilidade das substâncias calorigênicas: ioimbina, triiodotironina, aminofilina combinada a efedrina e fenilpropanolamina no tratamento da obesidade a curto prazo , 2000 .

[9]  P. Boileau.  Control of weight-gain during pregnancy: use of diethylpropion hydrochloride. , 1968, Applied therapeutics.

[10]  J. Little,et al.  Psychosis following readministration of diethyl proprion: a possible role for kindling? , 1993, International clinical psychopharmacology.

[11]  G. Bray,et al.  Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs. , 1978, The American journal of clinical nutrition.

[12]  V. Ricca,et al.  Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients , 1996, Journal of endocrinological investigation.

[13]  S. Booth,et al.  Effects of Orlistat on Fat‐Soluble Vitamins in Obese Adolescents , 2002, Pharmacotherapy.

[14]  E. Ravussin,et al.  Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women. , 1993, The American journal of clinical nutrition.

[15]  P. Ruelle,et al.  Prediction of carbazole solubility and its dependence upon the solvent nature , 1994 .

[16]  M. Goulder,et al.  Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. , 2001, The Journal of family practice.

[17]  T Brott,et al.  Phenylpropanolamine and the risk of hemorrhagic stroke. , 2000, The New England journal of medicine.

[18]  J. Hill,et al.  Effects of sibutramine on resting metabolic rate and weight loss in overweight women. , 1998, Obesity research.

[19]  A. Feinstein.  The measurment of success in weight reduction. An analysis of methods and new index. , 1959, Journal of chronic diseases.

[20]  S. Garattini,et al.  Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[21]  O. Bolding.  A double-blind evaluation of Tenuate dospan in overweight patients from a private gynecologic practice. , 1968, Journal of the Medical Association of the State of Alabama.

[22]  A. Prentice,et al.  Obesity in Britain: gluttony or sloth? , 1995, BMJ.

[23]  Roy A Kaplan,et al.  Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.

[24]  J. Whitehead,et al.  A one-year trial to assess the value of orlistat in the management of obesity. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[25]  B. Strauss,et al.  Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. , 1996, Obesity research.

[26]  T. Silverstone,et al.  The prolactin response to d- and I-fenfluramine and to d-amphetamine in human subjects , 1993, International clinical psychopharmacology.

[27]  L. V. Van Gaal,et al.  Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study , 1998, European Journal of Clinical Pharmacology.

[28]  Bauta Hp.  Evaluation of a new anorexic agent in adolescence. , 1974 .

[29]  L. J. Duncan,et al.  Comparison of continuous and intermittent anorectic therapy in obesity. , 1968, British medical journal.

[30]  A C IVY,et al.  The mechanism of amphetamine-induced loss of weight; a consideration of the theory of hunger and appetite. , 1947, Journal of the American Medical Association.

[31]  F. Lindgärde.  The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study , 2000, Journal of internal medicine.

[32]  J Miura,et al.  [Obesity and hypertension]. , 1992, Nihon rinsho. Japanese journal of clinical medicine.

[33]  S. Toubro,et al.  Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. , 1991, Metabolism: clinical and experimental.

[34]  T. Wadden,et al.  Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. , 1995, Obesity research.

[35]  O. Serri,et al.  Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[36]  J. Michnovicz.  Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol , 1998, International Journal of Obesity.

[37]  Bolding Ot.  Diethylpropion hydrochloride: an effective appetite suppressant. , 1974 .

[38]  J. Munro,et al.  Appraisal of the clinical value of serotoninergic drugs. , 1992, The American journal of clinical nutrition.

[39]  N. Weissman,et al.  An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. , 1998, The New England journal of medicine.

[40]  Romans Se,et al.  Psychosis following readministration of diethyl proprion: a possible role for kindling? , 1993 .

[41]  R. Vanbutsele,et al.  Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients , 2004, European Journal of Clinical Pharmacology.

[42]  A. Astrup,et al.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial , 2000, The Lancet.

[43]  J. Silverstone,et al.  The Long‐Term Management of Obesity in General Practice , 1965, The British journal of clinical practice.

[44]  T. Silverstone,et al.  The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. , 1990, International journal of obesity.

[45]  E. Carlini,et al.  A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats. , 1996, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[46]  E. Goodall,et al.  A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced Obesity , 1988, British Journal of Psychiatry.

[47]  L. V. Van Gaal,et al.  Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. , 1995, Metabolism: clinical and experimental.

[48]  R. E. Noble.  A six-month study of the effects of dexfenfluramine on partially successful dieters , 1990 .

[49]  S. Garattini.  Biological actions of drugs affecting serotonin and eating. , 1995, Obesity research.

[50]  S. Klein,et al.  Orlistat inhibits dietary cholesterol absorption. , 2001, Obesity research.

[51]  G. Slama,et al.  Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients. , 1978, Diabete & metabolisme.

[52]  G. Bray,et al.  A randomized double-blind clinical trial of fluoxetine in obese diabetics. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[53]  Smith Ig,et al.  Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. , 2001, The Journal of family practice.

[54]  P. D. Bewsher,et al.  Metabolic effects of fenfluramine--a double-blind study. , 1975, Postgraduate medical journal.

[55]  M. Visser,et al.  The effect of fluoxetine on body weight, body composition and visceral fat accumulation. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[56]  A. Astrup,et al.  The effect of long-term dexfenfluramine treatment on 24-hour energy expenditure in man. A double-blind placebo controlled study. , 1990, International journal of obesity.

[57]  G G Enas,et al.  Fluoxetine: a randomized clinical trial in the treatment of obesity. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[58]  P. Cowen,et al.  Hypophagic, endocrine and subjective responses to m‐chlorophenylpiperazine in healthy men and women , 1995 .

[59]  B. Goldstein,et al.  Beneficial health effects of modest weight loss. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[60]  A. Gallagher,et al.  A Study of Fluoxetine in Obese Elderly Patients with Type 2 Diabetes , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[61]  Mcquarrie Hg.  Clinical assessment of the use of an anorectic drug in a total weight reduction program. , 1975 .

[62]  B. Strupp,et al.  Modulation of the thermic effect of food by fenfluramine. , 1986, International journal of obesity.

[63]  M. Malone,et al.  Orlistat Use in Type 2 Diabetes , 2002, The Annals of pharmacotherapy.

[64]  J. Walsh,et al.  Dexfenfluramine in Type II diabetes: effect on weight and diabetes control , 1994, The Medical journal of Australia.

[65]  O. Bolding.  Diethylpropion hydrochloride: an effective appetite suppressant. , 1974, Current therapeutic research, clinical and experimental.

[66]  K. Fujioka,et al.  Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. , 2000, Archives of internal medicine.

[67]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[68]  P. Drouin,et al.  Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study , 1998, International Journal of Obesity.

[69]  R. A. Willims,et al.  Weight reduction in osteoarthritis using phentermine. , 1981, The Practitioner.

[70]  G. Baker,et al.  Metabolism and disposition of N-(2-cyanoethyl)amphetamine (fenproporex) and amphetamine: study in the rat brain. , 1986, Canadian journal of physiology and pharmacology.

[71]  M. G. Wallace,et al.  A multi-centre general practice trial of mazindol in the treatment of obesity. , 1977, The Practitioner.

[72]  R. Fuller,et al.  Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. , 1995, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[73]  J. Zavoral.  Treatment with orlistat reduces cardiovascular risk in obese patients , 1998, Journal of hypertension.

[74]  J. Zhi,et al.  Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers , 1995, Journal of clinical pharmacology.

[75]  C. Lintott,et al.  Dexfenfluramine reduces cardiovascular risk factors. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[76]  A. P. Truant,et al.  The oral bioavailability and pharmacokinetics of soluble and resin-bound forms of amphetamine and phentermine in man , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[77]  G. Bray,et al.  Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial. , 1977, International journal of obesity.

[78]  J. L. D. Luna del Castillo,et al.  Comparison of fluoxetine and placebo in the treatment of obesity. , 1995, Annals of nutrition & metabolism.

[79]  J. Feighner,et al.  Fluoxetine-induced weight loss in overweight non-depressed humans. , 1987, International journal of obesity.

[80]  L. Sjöström,et al.  Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[81]  N. Guvener,et al.  Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. , 2001, Diabetes care.

[82]  Tau Fluvalinate,et al.  The European Agency for the Evaluation of Medicinal Products , 1997 .

[83]  D C Rao,et al.  Influences of genes and shared family environment on adult body mass index assessed in an adoption study by a comprehensive path model. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[84]  L. Lissner,et al.  Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. , 1999, Obesity research.

[85]  M. Flechtner-Mors,et al.  Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women. , 1998, The American journal of clinical nutrition.

[86]  N. Cutler,et al.  Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial , 2002, Journal of Human Hypertension.

[87]  A. Rissanen,et al.  Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns , 2000, International Journal of Obesity.

[88]  A. Wirth,et al.  Long-term weight loss with sibutramine: a randomized controlled trial. , 2001, JAMA.

[89]  G. Frost,et al.  Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double‐blind, placebo‐controlled study , 2000, Diabetes, obesity & metabolism.

[90]  Willims Ra,et al.  Weight reduction in osteoarthritis using phentermine. , 1981 .

[91]  A. Golay,et al.  Lipoprotein distribution and composition in obesity: their association with central adiposity , 1997, International Journal of Obesity.

[92]  J. Overland,et al.  The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes , 1992, Diabetic medicine : a journal of the British Diabetic Association.

[93]  J. Gosden,et al.  A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine , 2005, Psychopharmacology.

[94]  D. Chapin,et al.  Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. , 1992, The American journal of clinical nutrition.

[95]  W H Dietz,et al.  Social and economic consequences of overweight in adolescence and young adulthood. , 1993, The New England journal of medicine.

[96]  E. Muls,et al.  The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study , 2001, International Journal of Obesity.

[97]  S. Peikin,et al.  Orlistat: its current status as an anti-obesity drug. , 2002, European journal of pharmacology.

[98]  A. Hill,et al.  Serotoninergic Drug Potentiates the Satiating Capacity of Food Action of d‐Fenfluramine in Obese Subjects , 1989 .

[99]  G. Williams,et al.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor , 2000, International Journal of Obesity.

[100]  T. Silverstone,et al.  Serotoninergic mechanisms in human feeding: The pharmacological evidence , 1986, Appetite.

[101]  S. Toubro,et al.  Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[102]  Maclay Wp,et al.  A multi-centre general practice trial of mazindol in the treatment of obesity. , 1977 .

[103]  G. Chouinard.  Sertraline in the Treatment of Obsessive Compulsive Disorder: Two Double‐blind, Placebo‐controlled Studies , 1992, International clinical psychopharmacology.

[104]  P. Vague,et al.  Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. , 1999, The American journal of medicine.

[105]  Goldstein Dj.  Beneficial health effects of modest weight loss , 1992 .

[106]  A. Dulloo,et al.  Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? , 1992, Metabolism: clinical and experimental.

[107]  H. Pijl,et al.  Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women , 1996, Clinical endocrinology.

[108]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[109]  M. Drent,et al.  Lipase inhibition: a novel concept in the treatment of obesity. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[110]  R R Wing,et al.  A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. , 1990, The American journal of psychiatry.

[111]  Langlois Kj,et al.  A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. , 1974 .

[112]  B. Guy-grand,et al.  INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY , 1989, The Lancet.

[113]  K. Shimamoto,et al.  Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. , 2000, Japanese circulation journal.

[114]  A. Feinstein,et al.  The treatment of obesity: an analysis of methods, results, and factors which influence success. , 1960, Journal of chronic diseases.

[115]  L. Bauman.  OBESITY: RECENT REPORTS IN THE LITERATURE AND RESULTS OF TREATMENT , 1928 .

[116]  S. Rössner,et al.  Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. , 2000, Obesity research.

[117]  K. Fujioka,et al.  Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension , 2000 .

[118]  B. Corya,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[119]  G. Bray,et al.  Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate. , 1999, The American journal of physiology.

[120]  S. Paul,et al.  (+)-Amphetamine binding to rat hypothalamus: relation to anorexic potency for phenylethylamines. , 1982, Science.

[121]  S. Paul,et al.  Glucostatic regulation of (+)-[3H]amphetamine binding in the hypothalamus: correlation with Na+,K+-ATPase activity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[122]  P. Bielmann,et al.  Effects of fenfluramine in hypertriglyceridemic obese subjects. , 1988, International journal of obesity.

[123]  H. Keen,et al.  Dextrofenfluramine in the treatment of refractory obesity , 1985 .

[124]  Adesh K. Jain,et al.  Sibutramine produces dose-related weight loss. , 1999, Obesity research.

[125]  J. Sowers,et al.  The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. , 1981, The New England journal of medicine.

[126]  B. Hazenberg.  Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Sibutramine in Obese Hypertensive Patients , 2001, Cardiology.

[127]  L. Darga,et al.  Fluoxetine's effect on weight loss in obese subjects. , 1991, The American journal of clinical nutrition.

[128]  H. Carmichael,et al.  Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[129]  J. Turtle,et al.  Hypoglycemic Action of Fenfluramine in Diabetes Mellitus , 1973, Diabetes.

[130]  D. Graham,et al.  Further cases of valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[131]  M. B. Andelman,et al.  Treatment of Obesity in Underprivileged Adolescents , 1967, Clinical pediatrics.

[132]  H. O'Connor,et al.  Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[133]  E. Mathus-Vliegen,et al.  Dexfenfluramine in the treatment of severe obesity: a placebo‐controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour , 1992, Journal of internal medicine.

[134]  K. Fujioka,et al.  Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus , 2000, Diabetes, obesity & metabolism.

[135]  G. Enzi,et al.  Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. , 1988, Clinical neuropharmacology.

[136]  P. Cowen,et al.  Ritanserin attenuates anorectic, endocrine and thermic responses tod-fenfluramine in human volunteers , 2005, Psychopharmacology.

[137]  Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. , 1996, JAMA.

[138]  L. Scalfi,et al.  The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[139]  A. Halpern,et al.  Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients , 2003, Diabetes, obesity & metabolism.

[140]  S. Garattini,et al.  Neurochemical mechanism of action of anorectic drugs. , 1993, Pharmacology & toxicology.

[141]  K. Fujioka,et al.  Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors , 2002, Journal of Human Hypertension.

[142]  P. Waller,et al.  Appetite suppressants and primary pulmonary hypertension in the United Kingdom. , 1995, British heart journal.

[143]  C. Dujovne,et al.  Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. , 2001, American heart journal.

[144]  L. Aronne,et al.  Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. , 2002, Diabetes care.

[145]  M. Stock,et al.  Sibutramine: a review of the pharmacology of a novel anti-obesity agent. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[146]  J Weissenburger,et al.  The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. , 1995, British journal of clinical pharmacology.

[147]  P. Collipp,et al.  Clinical Evaluation of the Anorexic Activity and Safety of 42-548 in Children , 1973, Clinical pediatrics.

[148]  B. Lerer,et al.  Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients , 1993, Biological Psychiatry.

[149]  J. Wurtman.  Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood. , 1990, Drugs.

[150]  G. Labó,et al.  Does ephedrine promote weight loss in low-energy-adapted obese women? , 1987, International journal of obesity.

[151]  G. Reaven,et al.  Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. , 2001, The American journal of cardiology.

[152]  P. Noël,et al.  Obesity , 2001, BMJ : British Medical Journal.

[153]  N. Milas,et al.  Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II , 2001, Annals of Internal Medicine.

[154]  S. Toubro,et al.  Thermogenic effects of sibutramine in humans. , 1998, The American journal of clinical nutrition.

[155]  D. Williamson.  Dietary intake and physical activity as "predictors" of weight gain in observational, prospective studies of adults. , 2009, Nutrition reviews.

[156]  H. Mcquarrie.  Clinical assessment of the use of an anorectic drug in a total weight reduction program. , 1975, Current therapeutic research, clinical and experimental.

[157]  R. McKay.  Long-term use of diethylpropion in obesity. , 1973, Current medical research and opinion.

[158]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[159]  Endocrine Drug Products,et al.  Guidance for the Clinical Evaluation of Weight-Control Drugs , 2001, Critical reviews in food science and nutrition.

[160]  G. Bray,et al.  Current and potential drugs for treatment of obesity. , 1999, Endocrine reviews.

[161]  M. Haney,et al.  Effect of Fluoxetine on Food Intake of Humans Living in a Residential Laboratory , 1996, Appetite.

[162]  Bolding Ot.  A double-blind evaluation of Tenuate dospan in overweight patients from a private gynecologic practice. , 1968 .

[163]  K. Heber.  DOUBLE‐BLIND TRIAL OF MAZINDOL IN OVERWEIGHT PATIENTS , 1975, The Medical journal of Australia.

[164]  P. Cowen,et al.  Sumatriptan decreases food intake and increases plasma growth hormone in healthy women , 1997, Psychopharmacology.

[165]  N. Ryley,et al.  Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM , 1997, International Journal of Obesity.

[166]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[167]  L. Aronne.  Modern medical management of obesity: the role of pharmaceutical intervention. , 1998, Journal of the American Dietetic Association.

[168]  J. Rey,et al.  Sibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity , 1999, The Annals of pharmacotherapy.

[169]  Sedgwick Jp.  Maziniol in the treatment of obesity. , 1975 .

[170]  I. Leck,et al.  PREVALENCE AND DURATION OF UNDETECTED BREAST CANCER , 1975, The Lancet.

[171]  N. Sakane,et al.  Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women. , 1994, International journal of clinical pharmacology research.

[172]  F. Musshoff,et al.  ILLEGAL OR LEGITIMATE USE? PRECURSOR COMPOUNDS TO AMPHETAMINE AND METHAMPHETAMINE , 2000, Drug metabolism reviews.

[173]  D. A. Seaton,et al.  Treatment of refractory obesity with fenfluramine. , 1966, British medical journal.

[174]  K. Jonderko,et al.  Extra-anorectic actions of mazindol. , 1989, Israel journal of medical sciences.

[175]  N. Finer.  Body weight evolution during dexfenfluramine treatment after initial weight control. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[176]  P. Cowen,et al.  Ondansetron, a 5‐HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers , 1992, International clinical psychopharmacology.

[177]  G. Medeiros-Neto,et al.  The effect of hypocaloric diet with and without D-fenfluramine treatment on growth hormone release after growth hormone-releasing factor stimulation in patients with android obesity. , 1994, Metabolism: clinical and experimental.

[178]  S. Daniels.  Pharmacological Treatment of Obesity in Paediatric Patients , 2001, Paediatric drugs.

[179]  R. Abramson,et al.  An evaluation of behavioral techniques reinforced with an anorectic drug in a double-blind weight loss study. , 1980, The Journal of clinical psychiatry.

[180]  T. Kelly,et al.  Effect of amphetamine on human macronutrient intake , 1995, Physiology & Behavior.